Stockscreener 앱 받기
5.16
2.38%
0.12
시간 외 거래:
5.16
Savara Inc 주식(SVRA)의 최신 뉴스
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MSN
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara grants inducement equity awards to new employee - MSN
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara says FDA review of MOLBREEVI to proceed without advisory committee - MSN
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch - streetwisereports.com
Growth Report: Will Savara Inc announce a stock splitForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026 - Meyka
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com - Investing.com Australia
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC - MarketBeat
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
VR Adviser Increases Savara Inc. Holdings in Q4 2025News and Statistics - IndexBox
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara receives FDA priority review for rare lung disease drug By Investing.com - Investing.com South Africa
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - The Joplin Globe
Rare lung disease drug MOLBREEVI nears key FDA decision on Aug. 22, 2026 - Stock Titan
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Savara (SVRA) Earnings Date and Reports 2026 - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook - simplywall.st
FY2030 Earnings Forecast for Savara Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara (SVRA) Advances MOLBREEVI Application with FDA and EMA - GuruFocus
Savara Provides Regulatory Update on the MOLBREEVI* Development P - The National Law Review
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Benzinga
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVIWhat's Changed - Yahoo Finance
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA). - Bitget
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases - geneonline.com
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):